Akoya Biosciences Revenue 2020-2021 | AKYA

Akoya Biosciences revenue from 2020 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Akoya Biosciences Annual Revenue
(Millions of US $)
2020 $42
2019 $42
Akoya Biosciences Quarterly Revenue
(Millions of US $)
2021-06-30 $13
2021-03-31 $12
2020-06-30 $9
2020-03-31 $11
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.584B $0.042B
Akoya Biosciences Inc. offers comprehensive single-cell imaging solutions which allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. The company offer distinct solutions, the CODEX(R) and Phenoptics(TM) platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. Akoya Biosciences Inc. is based in MARLBOROUGH, Mass.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29